This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agteresch, H. J. Articles by Dagnelie, P. C. Search for Related Content PubMed PubMed Citation Articles by Agteresch, H. J. Articles by Dagnelie, P. C.

Beneficial Effects of Adenosine Triphosphate on Nutritional Status in Advanced Lung Cancer Patients: A Randomized Clinical Trial

From the Departments of Internal Medicine and Medical Oncology, Erasmus University Medical Center, Rotterdam, and Department of Epidemiology, Maastricht University, Maastricht, the Netherlands.

Address reprint requests to P.C. Dagnelie, PhD, Department of Epidemiology, Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands; email: Dagnelie{at}epid.unimaas.nl

PURPOSE: In a randomized clinical trial in patients with advanced non–small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life. In the present article, the effects of ATP on body composition, energy intake, and energy expenditure as secondary outcome measures in the same patients are reported.

PATIENTS AND METHODS: Patients with NSCLC, stage IIIB or IV, were randomized to receive either 10 intravenous, 30-hour ATP infusions every 2 to 4 weeks or no ATP. Fat mass (FM), fat-free mass (FFM), and arm muscle area were assessed at 4-week intervals for 28 weeks. Food intake, body cell mass (BCM), and resting energy expenditure (REE) were assessed at 8-week intervals for 16 weeks. Between-group differences were tested for statistical significance by repeated-measures analysis of covariance.

RESULTS: Fifty-eight patients were randomized (28 ATP, 30 control). No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P = .004), 0.5 kg of FFM (P = .02), 1.8% of arm muscle area (P = .02), and 0.6% of BCM/kg body weight (P = .054) and decreased 568 KJ/d in energy intake (P = .0001). Appetite also remained stable in the ATP group but decreased significantly in the control group (P = .0004). No significant differences in REE between the ATP and control groups were observed.

CONCLUSION: The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues. These effects are partly ascribed to maintenance of energy intake.

This article has been cited by other articles:

				B. Winkens, H. J. A. Schouten, G. J. P. van Breukelen, and M. P. F. Berger Optimal designs for clinical trials with second-order polynomial treatment effects Statistical Methods in Medical Research, December 1, 2007; 16(6): 523 - 537. [Abstract] [PDF]

				J. Yin, K. Xu, J. Zhang, A. Kumar, and F.-S. X. Yu Wound-induced ATP release and EGF receptor activation in epithelial cells J. Cell Sci., March 1, 2007; 120(5): 815 - 825. [Abstract] [Full Text] [PDF]

				E. Shang, C. Weiss, S. Post, and G. Kaehler The Influence of Early Supplementation of Parenteral Nutrition on Quality of Life and Body Composition in Patients With Advanced Cancer JPEN J Parenter Enteral Nutr, May 1, 2006; 30(3): 222 - 230. [Abstract] [Full Text] [PDF]

				A. Jatoi and C. L. Loprinzi Adenosine Triphosphate: Does It Help Cancer Patients "Get Bigger and Stronger"? J. Clin. Oncol., January 15, 2002; 20(2): 362 - 363. [Full Text] [PDF]